205 related articles for article (PubMed ID: 23285138)
21. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
[TBL] [Abstract][Full Text] [Related]
22. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
Ghaffari SH; Bashash D; Dizaji MZ; Ghavamzadeh A; Alimoghaddam K
Tumour Biol; 2012 Feb; 33(1):157-72. PubMed ID: 22072212
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
24. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine.
Han YH; Kim SZ; Kim SH; Park WH
Mol Cells; 2008 Aug; 26(2):158-64. PubMed ID: 18596414
[TBL] [Abstract][Full Text] [Related]
25. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.
Ge F; Lu XP; Zeng HL; He QY; Xiong S; Jin L; He QY
J Proteome Res; 2009 Jun; 8(6):3006-19. PubMed ID: 19364129
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells.
Wang J; Peng X; Yang D; Guo M; Xu X; Yin F; Wang Y; Huang J; Zhan L; Qi Z
J Cell Mol Med; 2022 Jan; 26(2):563-569. PubMed ID: 34910369
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Xiao G; Tang X; Yao C; Wang C
Acta Biochim Biophys Sin (Shanghai); 2011 Sep; 43(9):712-21. PubMed ID: 21785114
[TBL] [Abstract][Full Text] [Related]
28. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH.
Han YH; Kim SZ; Kim SH; Park WH
Cancer Lett; 2008 Oct; 270(1):40-55. PubMed ID: 18539383
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.
Xu Y; Gu X; Gong M; Guo G; Han K; An R
Cancer Biol Ther; 2013 Oct; 14(10):897-906. PubMed ID: 23917726
[TBL] [Abstract][Full Text] [Related]
31. Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.
Zhang H; Su X; Guo L; Zhong L; Li W; Yue Z; Wang X; Mu Y; Li X; Li R; Wang Z
Int J Med Sci; 2014; 11(12):1262-9. PubMed ID: 25317073
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
You BR; Park WH
Oncol Rep; 2012 Aug; 28(2):749-57. PubMed ID: 22684917
[TBL] [Abstract][Full Text] [Related]
33. Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.
Hour TC; Huang CY; Lin CC; Chen J; Guan JY; Lee JM; Pu YS
Anticancer Drugs; 2004 Sep; 15(8):779-85. PubMed ID: 15494640
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism.
Bowling BD; Doudican N; Manga P; Orlow SJ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):37-43. PubMed ID: 18297286
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state.
Gartenhaus RB; Prachand SN; Paniaqua M; Li Y; Gordon LI
Clin Cancer Res; 2002 Feb; 8(2):566-72. PubMed ID: 11839678
[TBL] [Abstract][Full Text] [Related]
36. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.
Grad JM; Bahlis NJ; Reis I; Oshiro MM; Dalton WS; Boise LH
Blood; 2001 Aug; 98(3):805-13. PubMed ID: 11468182
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Liu Q; Hilsenbeck S; Gazitt Y
Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
[TBL] [Abstract][Full Text] [Related]
38. Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide.
Reberšek K; Žontar DM; Černelč P; Podgornik H
Hematology; 2014 Sep; 19(6):346-51. PubMed ID: 24165827
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
Guilbert C; Annis MG; Dong Z; Siegel PM; Miller WH; Mann KK
PLoS One; 2013; 8(12):e85995. PubMed ID: 24392034
[TBL] [Abstract][Full Text] [Related]
40. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH
J Biol Chem; 2009 May; 284(19):12886-95. PubMed ID: 19279006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
